| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043190712 |
| P356 | DOI | 10.1186/AR2276 |
| P932 | PMC publication ID | 2206383 |
| P698 | PubMed publication ID | 17688695 |
| P5875 | ResearchGate publication ID | 6150310 |
| P50 | author | Marvin J Fritzler | Q63302292 |
| P2093 | author name string | Ira N Targoff | |
| Martial Koenig | |||
| Jean-Luc Senécal | |||
| Yves Troyanov | |||
| P2860 | cites work | Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis | Q68717424 |
| The association between Mi-2 antibodies and dermatomyositis | Q68936700 | ||
| Antibodies against Ku protein in sera from patients with autoimmune diseases | Q69520069 | ||
| A novel autoantibody causing a peripheral fluorescent antinuclear antibody pattern is specific for nuclear pore complexes | Q70219579 | ||
| Multiplicity of antibodies in myositis sera | Q70387103 | ||
| Polymyositis-associated overlap syndromes | Q71066084 | ||
| Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis | Q71160324 | ||
| Anti-U5 small nuclear ribonucleoprotein (snRNP) antibodies: a rare anti-U snRNP specificity | Q71535858 | ||
| Classification and diagnostic criteria for polymyositis and dermatomyositis | Q72335441 | ||
| Comparative studies of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with systemic lupus erythematosus | Q72861351 | ||
| Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy | Q73501402 | ||
| Unicorns, dragons, polymyositis, and other mythological beasts | Q73797234 | ||
| Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival | Q77754710 | ||
| A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement | Q78794915 | ||
| Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis | Q80845187 | ||
| Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis | Q80955790 | ||
| [Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients] | Q81542191 | ||
| Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen | Q24678503 | ||
| Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182 | Q28181778 | ||
| Autoantibody to U3 Nucleolar Ribonucleoprotein (Fibrillarin) In Patients with Systemic Sclerosis | Q28289783 | ||
| Multiplexed particle-based flow cytometric assays | Q30925110 | ||
| Advances and applications of multiplexed diagnostic technologies in autoimmune diseases | Q33253420 | ||
| Clinical and serological associations of anti-Ku antibody. | Q33544522 | ||
| Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings | Q33861919 | ||
| Polymyositis and dermatomyositis (second of two parts) | Q33909233 | ||
| Polymyositis and dermatomyositis (first of two parts) | Q33911013 | ||
| Polymyositis: an overdiagnosed entity | Q34536136 | ||
| Clinical implications of autoantibody screening in patients with autoimmune myositis | Q34537296 | ||
| Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen | Q34564174 | ||
| Misunderstandings, misperceptions, and mistakes in the management of the inflammatory myopathies | Q34778745 | ||
| Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies | Q35036195 | ||
| Autoantibody profiles in the sera of European patients with myositis | Q35550062 | ||
| Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase | Q35610673 | ||
| Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients | Q36190260 | ||
| Analysis of human sera that are polyreactive in an addressable laser bead immunoassay | Q38468642 | ||
| Autoantibodies in systemic sclerosis | Q39726030 | ||
| A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups | Q40743626 | ||
| Classification criteria for the idiopathic inflammatory myopathies | Q41647350 | ||
| Nup180, a novel nuclear pore complex protein localizing to the cytoplasmic ring and associated fibrils | Q42250755 | ||
| Analysis of the autoantibody response to fibrillarin in human disease and murine models of autoimmunity | Q42830705 | ||
| Increased prevalence of autoantibodies to ku antigen in African American versus white patients with systemic lupus erythematosus | Q46348394 | ||
| Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex | Q46537792 | ||
| Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis | Q46894622 | ||
| Anti-fibrillarin antibodies in systemic sclerosis | Q46989762 | ||
| The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl | Q57089713 | ||
| Diagnostic criteria for polymyositis and dermatomyositis | Q58490815 | ||
| Anticentromere Autoantibodies | Q60449609 | ||
| Clinical, serologic, and immunogenetic features in polish patients with idiopathic inflammatory myopathies | Q61762667 | ||
| Antibody to signal recognition particle in polymyositis | Q61762714 | ||
| Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease | Q68099291 | ||
| P433 | issue | 4 | |
| P921 | main subject | heterogeneity | Q928498 |
| myositis | Q1433212 | ||
| patient | Q181600 | ||
| autoantibody | Q785022 | ||
| P304 | page(s) | R78 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes | |
| P478 | volume | 9 |
| Q38413380 | A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis |
| Q37154302 | Acute Onset Anti-Synthetase Syndrome With Pericardial Effusion and Non-Specific Interstitial Pneumonia |
| Q37679306 | Acute digital ischemia: A rare presentation of antisynthetase syndrome |
| Q38960509 | Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles |
| Q36150817 | An autoimmune myositis-overlap syndrome associated with autoantibodies to nuclear pore complexes: description and long-term follow-up of the anti-Nup syndrome |
| Q89886311 | Anti-HMGCR Antibody-Positive Myopathy Shows Bcl-2-Positive Inflammation and Lymphocytic Accumulations |
| Q52864090 | Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. |
| Q39572709 | Anti-Jo-1 myositis and the antiphospholipid syndrome showing right ventricular thrombus: a novel overlap syndrome with atypical presentation |
| Q58087535 | Anti-MDA5 Antibody Spectrum in Western World |
| Q35532333 | Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. |
| Q38809464 | Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. |
| Q41887990 | Anti-U3 ribonucleoprotein antibody-positive inflammatory myopathy: a case report |
| Q48285249 | Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsy. |
| Q34347058 | Anti-idiotypic monobodies for immune response profiling |
| Q38341312 | Antisynthetase syndrome: An under-recognized cause of interstitial lung disease |
| Q44098817 | Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-se |
| Q37613347 | Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype |
| Q52597638 | Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians? |
| Q81710056 | Autoantibodies and their significance in myositis |
| Q90415641 | Autoantibodies in Myositis. How to Achieve a Comprehensive Strategy for Serological Testing |
| Q38099556 | Autoantibodies in polymyositis and dermatomyositis |
| Q57814514 | Autoimmune Myopathies: Updates on Evaluation and Treatment |
| Q57756382 | Camptocormia as a clinical manifestation of polymyositis/systemic sclerosis overlap myositis associated with anti-Ku |
| Q34138964 | Clinical and laboratory aspects of Ro/SSA-52 autoantibodies |
| Q36469094 | Clinical and pathological roles of Ro/SSA autoantibody system. |
| Q38851103 | Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined by a novel chemiluminescent immunoassay |
| Q38116464 | Clinical heterogeneity and outcomes of antisynthetase syndrome |
| Q37670981 | Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies |
| Q37726608 | Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis |
| Q38086856 | Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis. |
| Q37824617 | Cutting edge issues in polymyositis |
| Q26863125 | Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies |
| Q36059517 | Diagnosis and treatment of inflammatory myopathy: issues and management |
| Q64102285 | Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases |
| Q51668925 | Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. |
| Q53375302 | Editorial: A New Classification of Adult Autoimmune Myositis. |
| Q35833312 | Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial |
| Q40130278 | Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study |
| Q39762134 | High frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis |
| Q37674765 | Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review |
| Q40322503 | Infections and vaccinations as possible triggers of inflammatory myopathies |
| Q89497679 | Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment |
| Q34296861 | Inflammatory myopathy and interstitial lung disease in antisynthetase syndrome with PL-7 antibody |
| Q37937430 | Interstitial Lung Disease in Idiopathic Inflammatory Myopathy. |
| Q35309739 | Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient! |
| Q37095730 | Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics |
| Q37368405 | Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research |
| Q37023594 | Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis |
| Q37480302 | Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression |
| Q43440724 | Necrotizing myopathy: clinicoserologic associations. |
| Q33572873 | New Insights into Antisynthetase Syndrome |
| Q59130847 | Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases |
| Q42213201 | Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis |
| Q39863980 | Prolidase deficiency breaks tolerance to lupus-associated antigens |
| Q36150826 | Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features |
| Q39114608 | Ro52/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies |
| Q41532980 | Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay |
| Q57755036 | Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis |
| Q45001327 | Severe dysphagia and erythrodermia in a 59-year-old man |
| Q35421571 | Significance of myositis autoantibody in patients with idiopathic interstitial lung disease |
| Q37226360 | Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations |
| Q40087587 | Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients |
| Q49910154 | The clinical phenotype of patients positive for antibodies to myositis and myositis-related disorders |
| Q84623589 | The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis |
| Q57225788 | The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren's syndrome |
| Q26796546 | Treatment of inflammatory myopathy: emerging therapies and therapeutic targets |
| Q84600744 | [Antibodies in systemic autoimmune diseases. Special mention to systemic lupus erythematosus] |
Search more.